Tazemetostat in Combination with Zanubrutinib and Rituximab or Obinutuzumab for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma, Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia or Follicular Lymphoma, TARZAN Trial

Inclusion Criteria

• Subject aged ≥ 18 years
• Eligible histologies include MCL, MZL (including splenic, nodal, and extranodal sub-types), and WM who received at least one line of prior systemic therapy and FL who received at least two prior lines of systemic therapy
• Measurable disease: at least one lesion > 1.5 cm in longest diameter or 1 extranodal lesion > 1 cm in the longest diameter. * Note: For MZL, isolated splenomegaly and involvement of any biopsy proven extranodal site is considered measurable for this study. For MCL, clonal lymphocyte measured by flow cytometry is considered measurable. For WM, serum IgM level > 0.5 g/dL is considered measurable
• Patients must have an indication for treatment * For R/R FL: active disease requiring treatment * For R/R MCL: active disease requiring treatment * For R/R MZL: active disease requiring treatment * For R/R WM: Meeting at least 1 criterion for treatment according to consensus panel criteria from the Seventh International Workshop on Waldenstrom's Macroglobulinemia ** Recurrent fever, night sweats, weight loss, fatigue ** Hyperviscosity ** Lymphadenopathy which is either symptomatic or bulky (≥ 5 cm in maximum diameter) ** Symptomatic hepatomegaly and/or splenomegaly ** Symptomatic organomegaly and/or organ or tissue infiltration ** Peripheral neuropathy due to WM ** Symptomatic cryoglobulinemia ** Cold agglutinin anemia ** Immune hemolytic anemia and/or thrombocytopenia related to WM ** Nephropathy related to WM ** Amyloidosis related to WM ** Hemoglobin < 10 g/dL ** Platelet count < 100,000/mm^3
• Eastern Cooperative Oncology Group (ECOG) performance status ≤ 2
• Absolute neutrophil count (ANC) ≥ 750 cells/mm^3 (≥ 0.75 x 10^9/L) independent of granulocyte colony-stimulating factor (G-CSF) support
• Platelet count ≥ 75,000 cells/mm^3 (≥ 75 x 10^9/L) independent of transfusion support
• Total bilirubin ≤ 1.5 x upper limit of normal (ULN) or ≤ 3 x ULN with document liver involvement and/ or Gilbert’s disease
• Aspartate aminotransferase (AST)(serum glutamic oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT)(serum glutamic pyruvic transaminase [SGPT]) ≤ 3 x institutional ULN * Subjects with liver involvement will be allowed to enroll with AST and ALT levels ≤ 5 x ULN
• Estimated creatinine clearance ≥ 30 mL/min by Cockcroft-Gault formula
• Adequate coagulation, defined as activated partial thromboplastin time (aPTT) or partial thromboplastin time (PTT) and prothrombin (PT) or international normalized ratio (INR) not greater than 1.5 x ULN
• Life expectancy of > 3 months, in the opinion of the investigator
• For female subjects: Negative pregnancy test or evidence of post-menopausal status. The post-menopausal status will be defined as having been amenorrheic for 12 months without an alternative medical cause. The following age-specific requirements apply: * Women < 50 years of age: ** Amenorrheic for ≥ 12 months following cessation of exogenous hormonal treatments; and ** Luteinizing hormone and follicle-stimulating hormone levels in the post-menopausal range for the institution; or ** Underwent surgical sterilization (bilateral oophorectomy or hysterectomy) * Women ≥ 50 years of age: ** Amenorrheic for 12 months or more following cessation of all exogenous hormonal treatments; or ** Had radiation-induced menopause with last menses > 1 year ago; or ** Had chemotherapy-induced menopause with last menses > 1 year ago; or ** Underwent surgical sterilization (bilateral oophorectomy, bilateral salpingectomy, or hysterectomy)
• Female subjects of childbearing potential and male subjects with a sexual partner of childbearing potential must agree to use a highly effective method of contraception and lactation requirements
• Subjects must agree to not breastfeed while on treatment or within 1 week of the last dose of tazemetostat or 2 weeks of zanubrutinib
• Ability to swallow oral tablets
• Patients or their legal representatives must be able to read, understand, and provide informed consent to participate in the trial
• Willing and capable of giving signed informed consent which includes compliance with the requirements and restrictions listed in the informed consent form (ICF) and in the protocol
• Time between prior anticancer therapy and first dose of tazemetostat as below: * Cytotoxic chemotherapy-At least 21 days * Non-cytotoxic chemotherapy (e.g., small molecule inhibitor)-At least 14 days * Monoclonal antibody(ies)-At least 28 days * Radiotherapy ** At least 14 days from local site radiation therapy ** At least 6 weeks from prior radioisotope therapy ** At least 12 weeks from 50% pelvic or total body irradiation * High-dose therapy with autologous hematopoietic cell infusion-At least 60 days * Chimeric antigen receptor T (CART) cell therapy-At least 60 days * Moderate CYP3A inhibitors-At least 3 elimination half-lives * Moderate CYP3A inducers-At least 14 days * Strong CYP3A inducers or inhibitors-At least 14 days * Note: Must be able to obtain zanubrutinib and anti-CD20 mAb commercially

Exclusion Criteria

• Prior exposure to tazemetostat or other inhibitor(s) of EZH2
• Any prior history of myeloid malignancies including myelodysplastic syndrome (MDS)/acute myeloid leukemia (AML) or myeloproliferative neoplasm (MPN)
• Any prior history of t-cell lymphoblastic lymphoma (T-LBL), T-acute lymphoblastic leukemia (T-ALL), or B-acute lymphoblastic leukemia (B-ALL)
• Clinically significant active malabsorption syndrome or other condition likely to affect gastrointestinal (GI) absorption of the study drugs
• Major surgery within 4 weeks prior to enrollment
• Known history of bleeding diathesis or active bleeding
• Known history of stroke or intracranial hemorrhage within 6 months of enrollment
• Significant cardiovascular disease defined as: * unstable angina or acute coronary syndrome within the past 2 months prior to study enrollment * history of myocardial infarction within 3 months prior to study enrollment or documented left ventricular ejection fraction (LVEF) by any method of ≤ 40% in the 12 months prior to study enrollment * ≥ grade 3 New York Heart Association (NYHA) functional classification system of heart failure, uncontrolled or symptomatic arrhythmias
• Significant liver disease (> Child Pugh class A)
• Patients with central nervous system (CNS) involvement
• Prolongation of the QT interval corrected for heart rate (QT interval corrected using Fredericia equation [QTcF]) > 480 msec. QTcF is calculated using Fridericia's formula (QTcF): QTcF = QT/(RR0.33) * Correction of suspected drug induced QTcF prolongation can be attempted at the investigator's discretion and only if clinically safe to do so with either discontinuation of the offending drug or switch to another drug not known to be associated with QTcF prolongation * Correction for underlying bundle branch block (BBB) allowed * Note: Patients with pacemakers are eligible if they have no history of fainting or clinically relevant arrhythmias while using the pacemaker
• Patients who have tested positive for human immunodeficiency virus (HIV)
• Known active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection based on criteria below: * Hepatitis B virus (HBV): Patients with positive hepatitis B surface antigen (HBsAg) are excluded. Patients with positive hepatitis B core antibody (anti-HBc) and negative HBsAg require hepatitis B polymerase chain reaction (PCR) evaluation before enrollment. Patients who are HBV deoxyribonucleic acid (DNA) PCR positive will be excluded. Patients with positive anti-HBc and negative HBV DNA should be on prophylactic nucleo(t)side analogue therapy to prevent reactivation with serial HBV DNA PCR monitoring * Hepatitis C virus (HCV): positive hepatitis C antibody. If positive hepatitis C antibody result, patient will need to have a negative result for hepatitis C ribonucleic acid (RNA) before enrollment. Patients who are hepatitis C RNA positive will be excluded
• Known cytomegalovirus (CMV) infection
• Evidence of other clinically significant uncontrolled condition(s) including but not limited to, uncontrolled systemic bacterial, viral, fungal, or parasitic infection (except for fungal nail infection), or other clinically significant active disease process which in the opinion of the investigator and medical monitor may pose a risk for patient participation. Screening for chronic conditions is not required
• Active uncontrolled auto-immune cytopenia (e.g., autoimmune hemolytic anemia [AIHA], idiopathic thrombocytopenic purpura [ITP]) for which new therapy was introduced or existing therapy was escalated within the 4 weeks prior to study enrollment to maintain adequate blood counts
• Active second malignancy unless in remission and with life expectancy > 2 years
• Patients requiring therapeutic anticoagulation with warfarin or another vitamin K antagonist
• Receipt of live virus vaccines within 28 days prior to the initiation of study treatment or need for live-virus vaccines at any time during study treatment
• Have a known hypersensitivity to any of the excipients of tazemetostat
• Subjects taking medications that are known strong CYP3A4 inducers or inhibitors and cannot come off the medication
• Subjects taking medications that are known moderate CYP3A inducers and cannot come off the medication